Clinical trial news

Illustration of a woman with a megaphone. Discussion

Children, teenagers, and adults with later-onset spinal muscular atrophy (SMA), previously treated with Evrysdi (risdiplam), can now enroll in a new Phase 3b clinical trial to determine the efficacy of a higher dose of Spinraza (nusinersen). Biogen, the company that markets Spinraza, announced the enrollment of…

Illustration of a handshake. Discussion

Biohaven Pharmaceuticals has entered into a worldwide licensing agreement to develop and commercialize Bristol Myers Squibb’s taldefgrobep alfa, a Phase 3-ready candidate therapy for spinal muscular atrophy (SMA). The company is planning to launch a Phase 3 trial to test the therapy (also known as BMS-986089) in…

top 10 | SMA News Today | illustration of top 10 Discussion

SMA News Today brought you daily coverage of the latest scientific findings, treatment developments, and clinical trials related to spinal muscular atrophy (SMA) throughout 2021. As a reminder of what mattered most to you during this year, here are the top 10 most-read articles of 2021 with a brief description of…

A half-full prescription medicine bottle bears a label reading 'Clinical Trials.' Discussion

Scholar Rock announced the full design of the upcoming Phase 3 clinical trial testing apitegromab, its experimental muscle-directed therapy for spinal muscular atrophy, in children and young adults with types 2 and 3 SMA who are unable to walk. Apitegromab will be given as an add-on therapy to…

Spinraza use linked to improved arm and hand function | SMA News Today | illustration of doctors using smart tablet Discussion

Scholar Rock is on track to initiate a pivotal Phase 3 trial of apitegromab in non-ambulatory patients with type 2 and type 3 spinal muscular atrophy (SMA) by the end of 2021, according to a company press release. The planned randomized, double-blind, and placebo-controlled trial will focus on people…